If your insurance stopped covering Wegovy mid-year, you usually have a short window before paying cash.
- Employer plans can cut benefits mid-year but owe written notice within 60 days of adoption.
- A formulary exception or a condition like sleep apnea can restore coverage.
- 10% of employers covering GLP-1s for weight management likely won’t in 2027 (Business Group on Health).

The notice tends to be short. Wegovy, Zepbound, and the other GLP-1 medicines will stop being covered for weight loss on a date that feels far too close. Plenty of people get no letter at all and find out their insurance stopped covering Wegovy at the pharmacy counter, when a refill that cost $25 last month rings up at more than $1,000.
You are not an edge case. As of July 2026, GoodRx’s coverage tracker counted 114 million people with no commercial coverage for Zepbound, 17 million more than in 2025, and 27 million with no coverage for Wegovy. Among people who do still have coverage for a weight-loss GLP-1, 88 percent face a restriction such as prior authorization. GoodRx notes that coverage changes through the year as plans add or remove drugs, and it sells prescription discounts to the people it counts, so read the figures as a dated snapshot from an interested source.
If your insurance stopped covering Wegovy in the middle of a plan year, the decision usually traces back to your employer, not the insurer. How the coverage ended also determines which options remain open to you, and a few of them close within weeks.
The order of what you do next matters more than most people expect: confirm what changed, collect the notice you are owed, file the short-window requests, and only then settle the self-pay question.
Table of Contents
Can my employer drop GLP-1 coverage in the middle of the year?
In most cases, yes. Self-funded employer plans can amend their own benefits at any point in the year, and at large companies they are the norm: 80% of covered workers at firms with 200 or more employees are in one, according to KFF’s 2025 survey.
Federal benefits law (ERISA) works as a disclosure law here: it requires the plan to tell you about changes in writing and sets deadlines for that notice, but it rarely forces an employer to keep covering a specific drug category. The Department of Labor’s plan-information rules spell out what administrators owe you: a Summary Plan Description (SPD) stating what the plan covers, and a written summary whenever the plan materially changes, both free of charge.
The name on your insurance card usually did not make the call. In 32 of the 67 coverage and appeal threads I reviewed on Reddit, the single most repeated correction was that the employer’s plan design decides GLP-1 coverage. The same carrier covers Zepbound for one member and excludes it for a neighbor because two employers bought two different plans. Benefits insiders in those threads put numbers on the pressure: one employer facing a $5 million annual GLP-1 bill was quoted premium increases between 4.5% and 10.5% depending on how much coverage it kept.
Fully insured and marketplace plans have less freedom mid-year. Several states restrict mid-year formulary changes or require advance notice, and the rules vary enough by state that no general article can settle your specific case. Two documents can: your plan’s own paperwork, and your state insurance department’s rules. If the plan comes through your employer, ask HR which kind of plan it is. The answer changes your leverage.
What notice does your plan owe you?
A group health plan that materially reduces benefits must tell you in writing within 60 days of adopting the change, under a federal disclosure regulation (29 CFR 2520.104b-3). Removing a drug category members rely on fits the rule’s own definition of a material reduction, which includes eliminating benefits and adding new requirements such as prior authorization. There is a wrinkle: plans that publish benefit updates on a regular cycle of 90 days or less can fold the announcement into that cycle instead.
Read the timing carefully. The 60 days run from when the change was adopted, and the rule does not promise warning before the change takes effect. In practice, many plans do better than the federal floor. One patient NPR spoke to, Deborah Finley, was given 90 days’ notice.
Put your requests in writing. Ask HR, or the plan administrator named in your documents, for the current SPD and the summary of material modifications covering the change. HR opacity is its own pattern in the threads: portals that ignore requests, staff who point at the insurer, insurers who point back at the employer. A written request creates a paper trail, and the SPD is a document the plan is legally required to hand over.
In the same message, ask whether a transition supply is available, meaning one or more refills honored while you arrange next steps. Some plans offer this after formulary changes. Nothing guarantees it on most commercial plans, and the drop threads report both outcomes, so ask early. The first week after your insurance stopped covering Wegovy is when transition and exception requests are strongest.
Two traps recur in the threads. A prior authorization approved through a future date is not a coverage guarantee; one member’s PA ran through October and the coverage still ended at the June 30 plan-year reset.
And the open-enrollment calendar can mismatch the formulary calendar. Formularies move at the January plan-year reset, and the move you are least likely to be told about is the one in your favour: plans owe you notice when a drug comes off the list, not when one goes back on. One r/Zepbound thread found Zepbound quietly restored to an employer’s Caremark formulary on January 1, a year after it had been dropped, with no notification sent to members. Check your own formulary at the reset rather than waiting to be told.
Facing a hard end date, people in 9 of the 67 threads described banking 90-day fills or spacing injections to stretch a stash. That is observed coping, not medical advice. Changing your dose schedule changes how the medicine works, so that conversation belongs with your prescriber.
Why has my insurance stopped covering Wegovy?
Cost, almost every time. Nearly eight in 10 employers say GLP-1s are driving an increase in their company’s health care costs, according to a Business Group on Health survey of 105 of its employer members, fielded in February and March 2026. Ellen Kelsay, the group’s president and CEO, said in the survey release that companies “cannot ignore the reality that GLP-1s have significant implications for health care budgets.” Among employers that cover GLP-1s for weight management today, 72% say they are likely to keep that coverage in 2027. Ten percent say they likely will not.
Coverage was never evenly spread. In KFF’s 2025 Employer Health Benefits Survey, 16% of firms with 200 to 999 workers covered GLP-1s primarily for weight loss, against 30% of firms with 1,000 to 4,999 workers and 43% of firms with 5,000 or more. Bigger firm, better odds.
The overall share barely moved, 19% of firms with 200 or more workers against 18% the year before: the biggest firms expanded coverage (43%, up from 28%) while 67% of firms with 200 or more workers that do not cover them say they are not likely to start within the next 12 months. Two-thirds of the largest covering firms also told KFF the drugs had a significant impact on their prescription spending. That spending line is the pressure behind every removal letter.
Public employers are making the same move. Massachusetts’ Group Insurance Commission, which covers about 460,000 members, ended coverage of GLP-1s prescribed for weight loss alone on July 1, 2026, while still allowing coverage for a qualifying condition such as cardiovascular disease, sleep apnea, or MASH when the doctor’s request shows the drug is treating it, and leaving diabetes prescriptions untouched. Weight loss alone excluded, condition-based coverage still possible on request: that structure is the shape most removals now take, and it is why the exception route matters so much.
There is one more variant. Sometimes your employer kept the benefit and the pharmacy benefit manager swapped brands, keeping Wegovy and dropping Zepbound or the reverse, because of rebate deals between PBMs and manufacturers. Those switches carry their own exception path, covered in the table below.
And sometimes nothing changed at all. The approval ran out. Cigna’s Zepbound weight-loss policy, for example, approves the drug for 8 months at first, and renewing it requires a loss of at least 5% from your weight before you started any GLP-1. That is a denied renewal rather than a removed benefit, so it is handled as an appeal.
Which route fits how you lost coverage?
Four different events all get reported as “they dropped my coverage,” and each one triggers different rights.
| What happened | What it triggers | Your best next move |
|---|---|---|
| Employer removed weight-loss GLP-1s mid-year (benefit exclusion) | Written notice within 60 days of adoption (federal SMM rule). Appeals rarely reverse an exclusion. | Screen for covered conditions with your doctor; if none qualify, run the self-pay numbers. |
| Insurer or PBM formulary change (your brand off the list, category still covered) | Formulary exception process; transition supply on many plans. | File the exception with documentation, or switch to the GLP-1 your plan kept. |
| New plan year began with an exclusion | No mid-year rights; the change was locked at renewal. | Qualifying-condition path now; check the formulary before next open enrollment. |
| Forced switch to a preferred brand (plan kept Wegovy, dropped Zepbound, or the reverse) | Exception path via documented failure or intolerance of the preferred drug. | Try the covered brand, or have your prescriber document why you cannot. |
Rows one and three are the hard ones. A benefit exclusion, where the employer removed the category, almost never overturns on appeal. In a thread of 98 physician comments on r/FamilyMedicine, the consensus ran that exclusion denials do not move, and external reviewers usually decline exclusion cases outright. A formulary removal is a different animal: the benefit category still exists, so a formulary exception request with documentation has a real path, and so does switching to whichever GLP-1 your plan still prefers. The comparison of the GLP-1 medications covers what changes if you move between Wegovy, Zepbound, and the others.
When can a formulary exception get Wegovy covered again?
A formulary exception asks the plan to cover a drug it took off the list, and it works when your prescriber documents why this specific medication is medically necessary for you. The strongest requests stack evidence: your response to the drug so far, reasons the alternatives are unsuitable, and any diagnosis the plan still covers GLP-1s for. Coverage that ended for weight loss alone often survives under another name. Under the Massachusetts change, coverage for sleep apnea, heart disease or MASH may still be approved once the doctor’s request shows the drug is treating that condition, and commercial plans run the same playbook.
Ask your doctor to screen you properly for those conditions. Undiagnosed diabetes is, in the words of Johns Hopkins Bloomberg School of Public Health professor of epidemiology and medicine Dr. Caleb Alexander, speaking to NPR, “the most likely scenario that would allow for someone to go from not being qualified to being qualified.” The pattern shows up in the community record too: formulary exception wins for moderate to severe sleep apnea appear across the threads I reviewed, including a member who won a UnitedHealthcare exception for Zepbound on a plan that excluded weight-loss coverage, after an eight-month fight. It does not always work: in 8 of the 67 threads, a blanket weight-loss exclusion defeated the sleep apnea route anyway.
If you are filing an exception request, the medical-necessity language is the hard part, and the free appeal letter template below has it written for you. Be clear about what a letter can do, though. If your employer removed the whole category, no letter overturns that decision; its realistic job is the exception request, the transition window, and any condition-based path. Where the category still exists, it is the main tool.
A fill-in-the-blank appeal letter built around your specific denial reason, with the medical-necessity language and deadlines already in place. You start from a finished draft, which turns the appeal into an afternoon’s work. Free, sent to your inbox.
Your template lands first, then a few helpful emails on GLP-1 coverage. Unsubscribe anytime.
How can I afford Wegovy if my insurance won’t cover it?
Self-pay is where most people land, and it has changed fast. In 39 of the 67 threads, the standard community answer to a coverage loss was a manufacturer direct-pay program: NovoCare pricing for Wegovy, LillyDirect vials or pens for Zepbound. Quoted prices shifted repeatedly over that time, so treat any specific number you read in a thread as dated, including the ones people swear by. Compounded versions appear in 30 of the threads as the post-denial exit ramp, at lower price points and with real caveats: compounded GLP-1s are not FDA-approved products, and NPR’s guidance is to verify the compounding pharmacy’s state license before buying anything.
The current numbers, branded against compounded against telehealth prescribing, with the manufacturer programs’ fine print, live in the GLP-1 cost comparison. If you are facing a hard exclusion with no qualifying condition, that comparison is your next stop.
Losing a medication that was working is a real loss, and the distress in these threads is not subtle. If the stress is weighing on you, tell your doctor or a counselor while you work through the practical steps. The longer arc offers some comfort too. Statins were once expensive and hard to get covered; now, Alexander notes, they are generic and often cost a few dollars. “I know it’s hard to imagine,” Alexander told NPR. “But there will come a day when we no longer see these access barriers for GLP-1s.”
What should you do in the 30 days after the coverage letter?
Day 1. Read the notice completely. Note the effective date, exactly what is excluded (the whole category or specific brands), and whether it names a transition supply or an exception process. Match what happened to the table above; the row you are in sets your week-one moves.
Week 1. Send HR or your plan administrator a written request for the Summary Plan Description and the summary of material modifications. Ask about a transition supply in the same message. Two asks, one email. Book your prescriber: you want a condition screen and, if anything qualifies, a formulary exception request filed while your refill history is current.
Weeks 2 to 4. If an exception is pending, follow up in writing and keep every reply. If the exclusion is total and no condition applies, run the self-pay numbers and pick the option you can sustain, because consistency matters more to your results than which discount you found. By day 30 you should know which of the three endings you are living with: coverage restored by exception, a switch to a covered GLP-1, or a self-pay plan with a monthly number you have accepted. The people who fared worst in the threads I reviewed spent the month arguing on the phone without filing anything. In the month after your insurance stopped covering Wegovy, paper beats phone calls.
This article is general information, not legal or insurance advice. Plan rules differ by employer, insurer, and state; read your own plan documents and confirm dates, criteria, and deadlines with your plan.
References
- GoodRx. Live Updates: Insurance Coverage for GIP and GLP-1 Agonists Like Zepbound & Wegovy in 2026. Reviewed on July 10, 2026. GoodRx sells prescription discounts. goodrx.com/healthcare-access/research/tracking-insurance-coverage-weight-loss-meds
- U.S. Department of Labor. Plan Information. dol.gov/general/topic/health-plans/planinformation
- 29 CFR 2520.104b-3, Summary of material modifications to the plan and changes in the information required to be included in the summary plan description. Electronic Code of Federal Regulations. ecfr.gov/current/title-29/subtitle-B/chapter-XXV/subchapter-C/part-2520/section-2520.104b-3
- Business Group on Health. GLP-1 Costs Loom Large for Employers, Forcing Challenging Coverage Decisions. Press release, 2026. businessgrouphealth.org/newsroom/news-and-press-releases/press-releases/2026-glp-1-survey
- KFF. 2025 Employer Health Benefits Survey. Published 22 October 2025. kff.org/health-costs/2025-employer-health-benefits-survey
- Massachusetts Group Insurance Commission. June Update on Vida Health Program and GLP-1 Coverage. 2026. mass.gov/news/june-update-on-vida-health-program-and-glp-1-coverage
- Cigna. Weight Loss, Glucagon-Like Peptide-1 Agonists, Zepbound. Drug Coverage Policy IP0816, effective September 1, 2026. static.cigna.com, policy IP0816 (PDF)
- Lupkin S. Trouble getting weight loss drugs covered by insurance? Here’s what to know. NPR, 23 June 2026. npr.org/2026/06/23/nx-s1-5793971/weight-loss-glp1-insurance-coverage
